Previous 10 | Next 10 |
Durect (NASDAQ: DRRX ): Q1 GAAP EPS of -$0.04 beats by $0.01 . More news on: DURECT Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
CUPERTINO, Calif. , May 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2019 and provided a corporate update, including preliminary data from the ongoing DUR-928 Phase 2a alcoholic hepatitis (AH) trial...
Durect (NASDAQ: DRRX ) is up 6.3% after hours, following up on an afternoon jump that hit 49% amid an update on an alcoholic hepatitis trial. More news on: DURECT Corporation, Healthcare stocks news, Stocks on the move, Read more ...
CUPERTINO, Calif. , May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March 31, 2019 after the market close on T...
CUPERTINO, Calif. , April 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors. Dr. Gail M. Farfel , Executive Vice President and Chief Development Officer of Zogenix, Inc., and Judith J. Rober...
The FDA has approved privately held NeuroSigma 's Monarch eTNS System for the first-line treatment of patients ages 7 - 12 years old with attention deficit hyperactivity disorder (ADHD), the first non-drug therapy for the condition available in the U.S. More news on: KemPharm, Inc., Sup...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
CUPERTINO, Calif. , April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg , Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m. EDT . ...
DURECT Corporation (NASDAQ: DRRX ) has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH. More news on: DURECT Corporation, Healthcare stocks news, Read more ...
CUPERTINO, Calif. , March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH. DUR-928, the lead investigational product in the Company's Epigenetic Regulator Pro...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...